Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$CBDW and Adnexus partnership news...
https://finance.yahoo.com/news/adnexus-biotechnologies-partners-1606-corp-120000325.html
Is Brixton Metals the stock to own NOW?
https://brixtonmetals.com/
Will the 2016 scenario play out again...? Probably.
Within 6 months this stock can make a 10X move.
https://www.barchart.com/stocks/quotes/BBB.VN/interactive-chart
BULLISH
$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year. This has been pre-announced in the last two IVDN news releases:
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
Strong Buy - see investing.com
https://www.investing.com/equities/carpathian-gold-inc.
ES Mines Confirm Validity of Mining Licence + Option to Extend (ESM)
https://www.globenewswire.com/news-release/20...xtend.html
Cayman Islands , Dollinger started NewCo (a shell cooperation) in exchange for 6.0 million common shares of NewCo.
PlantX has agreed to exchange a collection of PlantX assets including wholly owned subsidiaries Vegaste Technologies US Corp., Little West LLC, Plant Based Deli LLC, and PlantX Living Inc., and the Company's 53% interest in Portfolio Coffee, Inc. and 51% interest Eh Coffee Corp.
With cross-owning ( PlantX owning 60% of NewCo ) one uses a way to exchange assets (value) between the two companies, in order to reduce insight to the actual transactions controlled by Dollinger and the PlantX company.
A common way to be able to avoid paying taxes on the assets registred in the Cayman Islands - see full article on Yahoo; https://finance.yahoo.com/news/plantx-enters-...00531.html
I`m reducing my shares in the company, will sell all asap as the company are of interest to the regulatory authorities - the same/similar scandal appears to be investigated, as the Dollinger - Namaste insider crime 2019.
Do your own research always.
Fuse is Lit for Junior Miners , Next Target is US$2,500
https://brixtonmetals.com/
PlantX 0.7600 -0.4900 (-39.20%) CNSX
It seems like the problems for the company continues,
the week position with a 40% drop today is not good.
$AVRW News: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results
New Initiatives Showing Encouraging Results
SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company" , a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.
Key financial highlights for the fourth quarter included the following:
Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.
Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.
Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.
Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.
Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.
"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.
Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.
Operational Highlights
Other operational highlights during the fourth quarter of 2023 included:
Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/
About Avenir Wellness Solutions, Inc.
Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: http://www.avenirwellness.com.
About The Sera Labs, Inc.
Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: http://www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.
CONTACTS:
Investor Relations
Hanover International Inc.
T: (760) 564-7400
E: investor@avenirwellness.com
SOURCE: Avenir Wellness Solutions, Inc. (f/k/a Cure Pharmaceutical Holding Corp.)
Today`s News; Troilus Gold Corp Discovers New At-Surface Gold Zone 'West Rim' With Intercept of 1.37 g/t AuEq Over 11m Within 200m of Reserve Pit and Confirms Continuity of Zone X22 Mineralization to Depth of 550m
MAY 30, 2024, Montreal, Quebec – Troilus Gold Corp. (“Troilus” or the “Company”, TSX: TLG; OTCQX: CHXMF; FSE: CM5R) is pleased to announce the discovery of a new gold zone named the ‘West Rim Zone’ (“West Rim”) located within 200 metres west of the North Reserve Pit Shell (Zones 87, J & X22) (see Figure 1) in addition to assay results from Zone X22 (“X22”) at its Troilus Project, located in northcentral Quebec, Canada. The results herein are part of an ongoing 25,000m drilling campaign designed to expand and define select drill targets along the main mineral corridor and regionally.
Hole X22-24-080 Intercept Highlights:
Newly discovered “West Rim” intersected 1.37 g/t AuEq (1.32 g/t Au, 1.5 g/t Ag, 0.02% Cu) over 11 m within a broader intersection of 0.74 g/t AuEq (0.69 g/t Au, 1.78 g/t Ag, 0.02% Cu) over 32 m starting at just 21 m downhole (See Figure 2).
Zone X22 intersected 10.27 g/t AuEq (10.15 g/t Au, 0.50 g/t Ag, 0.07% Cu) over 1 m and 0.83 g/t AuEq (0.58 g/t Au, 1.45 g/t Ag, 0.15% Cu) over 30m incl. 13.85 g/t AuEq (12.55g/t Au, 9.10 g/t Ag, 0.76% Cu) over 1 m at 550 m depth (see Figure 2).
Justin Reid, CEO of Troilus Gold, commented, “After 5 years of systematic exploration, we are still making significant discoveries on the Troilus property. The West Rim target is a testament to the prospectivity and opportunity within proximity to the Troilus project’s mineral reserve pits defined in the recent Feasibility Study (see press release, May 14, 2024)*. Located just 200 meters from the North Reserve Pit and at surface, the West Rim is a highly prospective corridor spanning 4km in length, 1km of which has never been drilled and is open for follow up drilling and delineation of mineralization. Moreover, results from Zone X22 have extended mineralization past 500 meters depth, supporting the future potential of underground development. The geology team has continued to successfully discover and develop existing targets across the property, and we look forward to follow-up drilling in the coming months to build out the West Rim target and further extensions below the North Reserve Pit.”
* the completed NI 43-101 technical report associated with the Troilus Project FS will be available on SEDAR+ at www.sedarplus.ca under the Company’s issuer profile, as well as the Company’s website at www.troilusgold.com on or before June 28, 2024.
West Rim Zone
The West Rim Zone was discovered as part of an ongoing 25,000m drill program at the Troilus Property designed to test near-mine and regional priority drilling targets. The West Rim target is an exhalative stratigraphic horizon hosted within felsic to intermediate metavolcanic rocks along the north-west margin of the Troilus intrusion. This prospective sequence can be traced for more than 4 km from the hanging wall of the J Zone, continuing through the West Rim toward the Southwest hanging wall. The eastern boundary of the Troilus intrusion has been extensively explored, and reserves defined within the Z87 and SW Pits align along this eastern boundary. The western boundary of the diorite (West Rim) has been left un-explored and remains open to further drilling (see Figure 2 below).
Hole X22-24-080, reported today, was designed to test this horizon and to test X22 mineralization at depth. The West Rim horizon returned 0.74 g/t AuEq over 32 m including 1.37 g/t AuEq over 11 m starting at 21 metres downhole. This intercept is found within 200 metres to the southwest of the North Reserve Pit shell that includes Z87, ZJ and X22.
West Rim Zone Geology
Hole X22-24-080 shows a clear metallic zonation in the West Rim with a lower zinc-silver zone and an upper gold zone. Sulphide mineralization consists of disseminated, stringers veins, and small lenses of massive pyrrhotite, pyrite with accessory sphalerite and chalcopyrite transposed into the dominant foliation. The type of mineralization, alteration and the polymetallic signature suggests a gold-bearing VMS (Volcanogenic Massive Sulfides) system, which increases the prospectivity of the area to find larger and richer ore zones along strike and at depth. West Rim is a phase 1 target, which encompasses a combination of favourable volcanic/intrusive phases, geophysical anomalies, and attractive structural settings all located in proximity to the mine site, in areas with little drill coverage. Subsequent drilling phases include following up on high-grade trends at depth below the North Reserve Pit and drilling regional targets. An additional 1,700 metres of drilling has been allocated to follow up on the newly discovered West Rim trend.
Deep Drilling below North Pit – Extending X22 Mineralization at Depth
Results from X22-24-080 equally confirmed continuity of the mineralized system to depth below Zone X22, with broad mineralized intercepts of 0.83 g/t AuEq over 30 m and 0.38 g/t AuEq over 26 m, and continuous high-grade trends with intersections of 10.27 g/t AuEq over 1 m and 13.85 g/t AuEq over 1 m. The results also show the tonalitic phase of the Troilus intrusion, which hosts X22, appears to be thickening at depth. Data from deeper extension holes like X22-24-080 will be used to inform and update the ongoing drill program with a focus on expanding high-grade trends.
Zone X22 was identified in late 2022 at the southwestern border of Z87 open pit. 23,256 metres were drilled at X22, which successfully expanded the zone's mineral footprint from 300 metres to approximately 1 kilometre and confirmed a consistent pattern of continuous high-grade near-surface structures along this strike length. Although X22 only accounts for a small portion of the 322,000 metres drilled at Troilus since 2018, it has contributed 1.19Moz AuEq (59.2Mt at 0.62 g/t AuEq) or 11% of total open pit Indicated mineral resources (see press release, October 16, 2023).
Previously Reported Highlights from open high-grade trends of X22:
(see Table 2 for breakdown by metal)
September 7th, 2023:
10.73 g/t AuEq over 10 m incl. 19.07 g/t AuEq over 3 m and 41.98 g/t AuEq over 1 m (X22-24-071), and 32.48 g/t AuEq over 0.8 m (X22-23-075).
July 11th, 2023:
104.12 g/t AuEq over 1 m from (X22-23-042), 15.57 g/t AuEq over 1 m, 26.14 g/t AuEq over 1 m (X22-23-059), 3.32 g/t AuEq over 11 m incl. 24.60 g/t AuEq over 1 m and 3.11 g/t AuEq over 17 m incl. 7.26 g/t AuEq over 3 m (X22-23-066), and 133.15 g/t AuEq over 0.7 m (X22-23-067).
May 9th, 2023:
3.54 g/t AuEq over 6m from hole X22-23-031, 8.73 g/t AuEq over 4m incl. 25.35 g/t AuEq over 1m (X22-23-032), 6.59 g/t AuEq over 3 m (X22-23-033), and 14.41 g/t AuEq over 1.2 m (X22-23-036)
April 25th, 2023:
6.74 g/t AuEq over 3 m incl. 15.58 g/t AuEq over 1 m (X22-23-006) and 131.86 g/t AuEq over 1 m (X22-23-030).
March 30th, 2023:
8.09 g/t AuEq over 2 m (X22-23-023)
March 23rd, 2023:
11.18 g/t AuEq over 6 m including 27.70 g/t AuEq over 2 m (X22-23-027).
Further drilling of underground targets is planned below the North Reserve Pit, near Zone 87, which has open high-grade shoots plunging with the dominant stretching lineation last drilled in October 31, 2018 and demonstrated extensions below the mineral resource pits. See table 3 for breakdown by metal.
Figure 1 – Plan View of West Rim Showing Current and Previously Reported Drill Holes
View Larger Image
Figure 2 – Geology Map of the Troilus Deposit Showing Current and Previously Reported Drill Holes
View Larger Image
Table 1 – X22-24-080 Drill Results
Hole From
(m) To
(m) Interval
(m) Inside/Outside
of FS Reserve Pit Au
Grade
(g/t) Cu
Grade
(%) Ag
Grade
(g/t) AuEq*
Grade
(g/t)
X22-24-080
21 53 32 outside 0.69 0.02 1.78 0.74
incl 32 43 11 outside 1.32 0.02 1.5 1.37
232 233 1 outside 0.66 0.77 27.5 2.22
270 273 3 outside 0.47 0.19 1.67 0.79
442 448 6 outside 0.17 0.09 0.33 0.31
478 479 1 outside 10.15 0.07 0.5 10.27
567 597 30 outside 0.58 0.15 1.45 0.83
incl 587 588 1 outside 12.55 0.76 9.1 13.85
628 629 1 outside 1.37 0.23 1.7 1.75
642 668 26 outside 0.28 0.06 0.76 0.38
incl 643 644 1 outside 1.2 0.21 1.3 1.54
incl 663 668 5 outside 0.56 0.15 2.42 0.83
* AuEq = Au + 1.5628 x Cu + 0.0128 x Ag
Table 2 – Previously Reported Results from Zone X22
Hole From
(m) To
(m) Interval
(m) Inside/Outside
of FS Reserve Pit Au
Grade
(g/t) Cu
Grade
(%) Ag
Grade
(g/t) AuEq*
Grade
(g/t)
X22-23-027 (March 23, 2023)
160 166 6 inside 9.42 0.88 30.10 11.18
incl 161 163 2 inside 23.22 2.21 80.30 27.70
X22-23-023 (March 30, 2023)
177 179 2 inside 7.75 0.19 3.00 8.09
X22-23-006 (April 25, 2023)
164.45 171 6.55 inside 3.24 0.02 5.46 3.35
incl 168 171 3 inside 6.59 0.02 9.30 6.74
incl 170 171 1 inside 15.35 0.03 14.60 15.58
X22-23-030 (April 25, 2023)
65 66 1 inside 126.50 2.85 71.00 131.86
X22-23-031 (May 9, 2023)
142 148 6 inside 2.04 0.37 72.03 3.54
X22-23-032 (May 9, 2023)
72 76 4 inside 8.22 0.24 10.45 8.73
incl 73 74 1 inside 24.10 0.59 25.80 25.35
X22-23-033 (May 9, 2023)
77 80 3 inside 5.86 0.38 10.63 6.59
X22-23-036 (May 9, 2023)
57 58.2 1.2 inside 14.25 0.08 2.80 14.41
X22-23-042 (July 11, 2023)
166 167 1 inside 102.50 0.82 26.80 104.12
X22-23-046 (July 11, 2023)
224 225 1 outside 15.55 0.01 0.25 15.57
X22-23-059 (July 11, 2023)
96 97 1 inside 25.90 0.10 6.20 26.14
X22-23-066 (July 11, 2023)
198 209 11 inside 3.20 0.06 2.16 3.32
incl 201 202 1 inside 24.40 0.07 6.90 24.60
343 360 17 outside 3.04 0.04 0.52 3.11
incl 351 354 3 outside 7.24 0.01 0.25 7.26
X22-23-067 (July 11, 2023)
171.6 172.3 0.7 inside 133.00 0.07 3.40 133.15
X22-23-071 (September 7, 2023)
379 389 10 outside 7.63 1.51 57.77 10.73
incl 379 382 3 outside 10.24 4.42 150.00 19.07
incl 388 389 1 outside 40.20 0.42 87.50 41.98
X22-23-075 (September 7, 2023)
104 104.8 0.8 outside 32.40 0.04 1.20 32.48
* AuEq = Au + 1.5628 x Cu + 0.0128 x Ag and has been updated since original release
Table 3 – Previously Reported Results from Zone 87 (October 31, 2018)
Hole From
(m) To
(m) Interval
(m) Inside/Outside
of FS Reserve Pit Au
Grade
(g/t) Cu
Grade
(%) Ag**
Grade
(g/t) AuEq
Grade
(g/t)
TLG-Z8718-017
643 685 42 outside 2.61 0.08 NA 2.74
incl 671 673 2 outside 42.30 0.12 NA 42.49
TLG-Z8718-018
675 727 52 outside 1.88 0.10 NA 2.04
incl 684 692 8 outside 4.49 0.18 NA 4.77
incl 700 712 12 outside 3.11 0.10 0.00 3.27
TLG-Z8718-035
689 770 81.00 outside 1.44 0.13 NA 1.64
incl 707 710 3.00 outside 8.25 0.54 NA 9.09
incl 755 765 10 outside 3.23 0.30 NA 3.70
TLG-Z8718-44W
832 899 67 outside 1.58 0.10 NA 1.74
incl 874 876 2 outside 10.03 0.35 NA 10.58
incl 881 887 6 outside 7.54 0.17 NA 7.81
* AuEq = Au + 1.5628 x Cu + 0.0128 x Ag and has been updated since original release
* NA = Not Analyzed. AuEq calculated using value of 0.00 g/t Ag
Quality Assurance and Control
During the drill program, one meter assay samples were taken from NQ core and sawed in half. One-half was sent for assaying at ALS Laboratory, a certified commercial laboratory, and the other half was retained for results, cross checks, and future reference. A strict QA/QC program was applied to all samples; which included insertion of one certified mineralized standard and one blank sample in each batch of 25 samples. Every sample was processed with standard crushing to 85% passing 75 microns on 500 g splits. Samples were assayed by one-AT (30 g) fire assay with an AA finish and if results were higher than 3.5 g/t Au, assays were redone with a gravimetric finish. For QA/QC samples, a 50 g fire assay was done. In addition to gold, ALS laboratory carried out multi-element analysis for ME-ICP61 analysis of 33 elements four acid ICP-AES.
Qualified Person
The technical and scientific information in this press release has been reviewed and approved by Nicolas Guest, P.Geo., Exploration Manager, who is a Qualified Person as defined by NI 43-101. Mr. Guest is an employee of Troilus and is not independent of the Company under NI 43-101.
AuEq Disclosure
The formulas used to calculate equivalent values for resources are as follows, for 87 Pit AuEq = Au + 1.5628*Cu +0.0128 *Ag, for J Pit AuEq = Au + 1.5107*Cu +0.0119 *Ag, for SW Pit AuEq = Au + 1.6823*Cu +0.0124 *Ag, for X22 Pit AuEq = Au + 1.5628*Cu +0.0128 *Ag. AuEq was calculated using metal prices of $1,850/oz Au; $4.25/lb Cu and $23.00/oz Ag.
About Troilus Gold Corp.
Troilus Gold Corp. is a Canadian development-stage mining company focused on the systematic advancement of the former gold and copper Troilus Mine towards production. Troilus is located in the tier-one mining jurisdiction of Quebec, Canada, where it holds a large land position of 435 km² in the Frôtet-Evans Greenstone Belt. A Feasibility Study completed in May 2024 supports a large-scale 22-year, 50ktpd open-pit mining operation, positioning it as a cornerstone project in North America.
For more information:
Caroline Arsenault
VP Corporate Communications
+1 (647) 407-7123
info@troilusgold.com
Romania Government Align Mining Legislation to EU 's Critical Raw Materials Act
https://crweworld.com/article/news-provided-by-globenewswire/3364861/romania-government-announces-strategy-to-align-mining-legislation-to-the-eu-s-critical-raw-materials-act
https://www.eurosunmining.com/
BULLISH
$RENB News: Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy
LOS ANGELES and AMSTERDAM, May 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) and the Amsterdam UMC Cancer Center today announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy. Both Renovaro and Amsterdam UMC emphasize the need to carry out the appropriate corporate and scientific due diligence before taking these next steps. Alongside the independent validation any final contractual commitments are subject to approval from both executive boards.
This collaboration would bring together Renovaro's proprietary cancer vaccine technology and the Cancer Center's expertise in several ancillary immunomodulatory technologies, towards innovative advancements in cancer treatment.
The proposed “Newco” will be headquartered in Amsterdam, The Netherlands. By merging Renovaro's cutting-edge vaccine technology with the Cancer Center's expertise, the aim is to develop personalized cancer immunotherapy solutions tailored to individual patients, overcoming immunotherapy resistance.
"We believe that by combining our expertise in cancer research and therapy with Renovaro's innovative allogenic dendritic vaccine technology, we can accelerate the development of personalized cancer treatments," said Prof. Geert Kazemier, Director of the Amsterdam UMC Cancer Center. "This once again represents our commitment to advancing cancer immunotherapy and improving patient outcomes."
"We are thrilled to partner with the Amsterdam UMC Cancer Center to drive innovation in cancer immunotherapy," said Coenraad K. van Kalken MD PhD, Director of RenovaroCube. "This collaboration represents a recognition of our potentially transformative technologies and a strategic alignment of our shared vision to change cancer treatment through personalized medicine. Also, as part of the MoU certain clinical activities would be moved to Amsterdam."
This new venture will operate independently, with a dedicated team of researchers collaborating closely with experts from both RenovaroBio and the Amsterdam UMC Cancer Center and will benefit from the combined resources, expertise, and extensive networks of its parent organizations, ensuring a strong foundation for success.
Both Renovaro and the Amsterdam UMC Cancer Center believe that the commitment to driving innovation in more non-invasive cancer therapies will enable significant strides in the fight against cancer, offering hope to patients worldwide.
About Renovaro Group:
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. We believe this will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
About Amsterdam UMC/ CCA
With over 16,000 employees and 1,400 beds, Amsterdam UMC is one of the largest University Hospitals in the Benelux. The two locations of Amsterdam UMC, merged in 2020, work together to provide good and accessible care for millions of people. Amsterdam UMC focuses on a future where diseases can be prevented and where patients receive the best treatments. Amsterdam UMC has eight research institutes, the largest being the Cancer Center. The VUmc location (former Free University Hospital) emphasizes cancer and neurodegenerative disease research. The researchers affiliated are internationally recognized among the top in medical scientific research.
The Cancer Center Amsterdam was founded as a research institute over 25 years ago by Prof. Bob Pinedo and his colleagues to pursue innovative cancer research. Today, Cancer Center Amsterdam has become much more than an academic oncology center, encompassing all cancer care, research, and education at Amsterdam UMC. It is also aligned with the Cancer Center Amsterdam Foundation, which raises funds to empower promising developments in oncology research and patient care at Amsterdam UMC, and with Amsterdam UMC Holding, the corporate entity set up to actively bring highly promising medical innovation to the market.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTEyMzQ1MyM2MjY4MjU3IzIxMjA2Nzk=
https://ml.globenewswire.com/media/NmVlM2U4YTItMmZkMi00OGY5LTkzNzAtODVkZjA3Y2Y0YjE5LTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
PlantX has BREAKOUT NOW see the chart on OTC
PLANTX Life 1 year forecast $3.5310, a +17082.70%
increase from the current price of $0.0206.
https://stockscan.io/stocks/PLTXF/forecast
(170X probably to good 2 be true
https://vegainvestors.com/
https://investorshub.advfn.com/PlantX-Life-Inc-VEGA-38643
$GNPX:Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024
Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Designations
AUSTIN, Texas, May 14, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient has been enrolled and dosed in the Company's Phase 1 dose escalation portion of the Acclaim-3 clinical study of Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy in combination with Genentech's Tecentriq® to treat patients with extensive-stage small cell lung cancer (ES-SCLC).
"We are excited to take this next step in our fight against lung cancers as we work to advance an innovative therapy that we believe provides hope to patients suffering with ES-SCLC, an especially aggressive form of lung cancer that has extremely limited treatment options," said Ryan Confer, President and Chief Executive Officer at Genprex. "With a median progression free survival (PFS) of 5.2 months, ES-SCLC has a particularly poor prognosis. Additionally, patients receiving Tecentriq as maintenance therapy have a median PFS of 2.6 months after the start of maintenance therapy. With such limited benefit from current treatments, we believe the combination of REQORSA and Tecentriq can provide a promising new therapeutic option for the treatment of small cell lung cancer."
"The Phase 1 dose escalation portion of the Acclaim-3 study is expected to determine the maximum tolerated dose for the Phase 2 expansion study," stated Mark Berger, M.D., Chief Medical Officer of Genprex. "The favorable results from our Phase 1 Acclaim-1 study in non-small cell lung cancer (NSCLC) enabled us to shorten the Phase 1 portion of Acclaim-3. This should allow us to complete the Phase 1 portion of the study during the second half of 2024 and to advance more quickly into the Phase 2 expansion portion of Acclaim-3 in the second half of 2024. We look forward to providing study updates as we advance this potentially life-saving therapy to benefit patients battling ES-SCLC."
Genprex has a novel cancer treatment platform that re-expresses tumor suppressor genes in cancers. Tumor suppressor genes are often deleted or inactivated early in the process of cancer development. REQORSA contains a plasmid that expresses TUSC2, a tumor suppressor gene protein. Nearly 100% of SCLCs have reduced or no TUSC2 protein expression, and 41% completely lack TUSC2 protein expression. Nonclinical studies in mice support the hypothesis that re-expressing the TUSC2 protein may lead to improved clinical efficacy in combination with Tecentriq.
About the Acclaim-3 Clinical Trial
The Acclaim-3 clinical trial is a Phase 1/2 open-label, dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq in patients with ES-SCLC. The Acclaim-3 clinical trial will enroll patients who did not develop tumor progression after receiving Tecentriq and chemotherapy as standard initial treatment, and who are therefore eligible for maintenance therapy.
The Phase 1 dose escalation portion of the Acclaim-3 clinical study is expected to enroll up to 12 patients at approximately ten U.S. clinical sites to determine the Maximum Tolerated Dose (MTD). If no dose limiting toxicities occur during the Phase 1 study, the highest dose evaluated will be the Recommended Phase 2 Dose. The Phase 2 portion of the study is expected to enroll approximately 50 patients at ten to fifteen U.S. sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. Genprex expects to initiate the Phase 2 expansion study in the second half of 2024.
The primary endpoint of the Phase 2 portion of the trial is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq treatment in patients with ES-SCLC. Patients will also be followed for survival. A Phase 2 futility analysis will be performed after the 25th patient enrolled and treated reaches 18 weeks of follow up.
Genprex has received U.S. Food and Drug Administration (FDA) Ophran Drug and Fast Track designations for Reqorsa® Immunogene Therapy, in combination with Genentech, Inc's Tecentriq® in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Additional information about the Acclaim-3 clinical trial can be found by visiting ClinicalTrials.gov.
About Reqorsa® Immunogene Therapy
Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy for NSCLC and SCLC consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles made from lipid-based molecules in a lipoplex form (Genprex's Oncoprex® Delivery System) with a positive electrical charge. REQORSA is injected intravenously and specifically targets cancer cells, which generally have a negative electrical charge. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells. In addition, REQORSA disrupts the metabolism of cancer cells by decreasing glycolysis and ATP production in cancer cells with decreased TUSC2.
Genprex's strategy is to develop REQORSA in combination with currently approved therapies and believes that REQORSA's unique attributes position it to provide treatments that improve on current therapies for patients with NSCLC, SCLC, and possibly other cancers.
Tecentriq® is a registered trademark of Genentech, Inc.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy, is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
$RENB News: Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer.
Traditional cancer detection methods often fall short in identifying cancers at an early stage when treatment is the most effective. However, Flamingo has the potential to overcome these limitations by harnessing the power of AI to analyze minute amounts of cfDNA data that is highly accurate.
"At RenovaroCube, we believe in pushing the boundaries of possibility," states Daan Vessies, senior scientist at RenovaroCube. "Flamingo undescores our commitment to change cancer diagnostics in a transformative way, ultimately offering clinicians a powerful tool to detect cancer across diverse omic layers."
The Company believes that no single model or molecular modality will reach the requisite sensitivity and specificity throughout the entire patient journey for personalized, precision medicine, from early detection, to predicting the effectiveness of various treatment options, to monitoring the response to therapy within days of starting it, to detecting recurrence at the earliest possible moment. Therefore, our AI/machine learning platform, The Cube, integrates multi-omic data, offering a uniquely comprehensive approach to cancer detection by leveraging a library of trained models for multiple omic layers. One such model Flamingo focuses on is the detection of cancer from ultra-low pass whole genome sequencing (ULP-WGS) cfDNA data using fragmentomics.
Flamingo's development marks a significant milestone in the quest for early cancer detection with RenovaroCube’s engine. By utilizing as few as only 200,000 cell-free DNA fragments per sample, integrating fragment lengths, sequence motifs and employing a meticulously designed neural network, Flamingo achieves remarkable performance in distinguishing cancer from healthy samples.
By augmenting The Cube's arsenal of models operating across various omic layers, Flamingo contributes to the development of non-invasive diagnostics to detect cancer early, enabling timely interventions and improving patient outcomes.
"Adding Flamingo to our Cube will accelerate our efforts to realize a paradigm shift in cancer detection," affirms Frank van Asch, CTO, RenovaroCube. "With its introduction, we are one step closer to realizing our vision of a world where cancer is detected and treated swiftly, saving countless lives in the process."
RenovaroCube invites interested doctors and scientists from international research institutions, clinical cancer centers and all stakeholders to join in the early research use application of our AI/machine learning platform to advance cancer diagnostics and pave the way for a healthier future.
About Renovaro:
Please see a recent interview with Avram Miller, Member of, and Advisor to, the Board of Directors, former co-founder of Intel Capital and SVP of Business Development for Intel:
https://techbullion.com/avram-miller-talks-ab...es-with-ai
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes RenovaroBio, with its advanced cell-gene immunotherapy company, and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
https://www.renovarogroup.com
https://www.renovarobio.com
https://www.renovarocube.com
About Cyclomics:
Cyclomics is a Dutch company founded in 2018, winner of the Health Holland Venture Challenge (startup of the year) by scientists of the UMC Utrecht. Its ambition is to transform cancer care by enabling faster and more reliable diagnoses, particularly in the context of cancer recurrence thanks to its proprietary circulating tumor DNA (ctDNA) detection technology.
https://www.cyclomics.com/
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
Chicago’s New Essential Taco Restaurants!
https://vegainvestors.com/news/chicagos-essen...staurants/
https://investorshub.advfn.com/PlantX-Life-Inc-VEGA-38643
(next week earningsreport)
PlantX Today NO RESISTANCE;
3rd Resistance Point 0.0250
2nd Resistance Point 0.0250
1st Resistance Point 0.0250
Last Price 0.0250
1st Support Level 0.0250
2nd Support Level 0.0250
3rd Support Level 0.0250
Earnings report announced to come today
$AVRW: Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our unique and proprietary skin care formulations. With 15 patents under our control, the highly positive reviews Seratopical DNA Complex is receiving, and more new products in development, 2024 is set up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward.
Sincerely,
Nancy Duitch, CEO
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
ALCOHOL! New Video PlantX CEO Sean Dollinger Spills Secrets
in Interview with Michael Nauss!
$IVDN (16 million float) News on Rising Sales of Superior Insulation Product: Innovative Designs Vendor Growth
PITTSBURGH, PA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs, Inc. (OTCQB: IVDN) continues to gain market share through its growing vendor base. Since the beginning of this fiscal year (November 1, 2023), Innovative Designs has added over 30 new accounts that have purchased its Insultex House Wrap®. This has resulted in a comp sales increase of 318% as compared to the same time period last year (November 2022 – April 2023). With 7 months remaining in FY2024, sales for the first 5 months are approaching 88% of last year's total.
Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
Website: http://www.insultexhousewrap.com
Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html
The Past, Present and Future of PlantX Life Inc. (recorded last year)
Analysts target price range for PlantX Life Inc. The bear-bull range indicates that the price target lies between CA$0.89 and CA$4.821 The stock trades also on the OTC.
The board; https://investorshub.advfn.com/PlantX-Life-Inc-VEGA-38643
STRONG BUY barchart.com Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions. Long term indicators fully support a continuation of the trend. barchart.com PlantX will finally bounce back!
Under the radar SODE: Annual report and current filing: 1) unrestricted shares a measly 31M only 2) gross profit 3) no change in OS for years 4) no convertible debt...entry pps IMO...spike from under a cent to $1 pps in 2021; spike to 10 cent pps in 2022
https://www.otcmarkets.com/stock/SODE/disclosure
$CBMJ Launched PATRIOT.TV and is already gaining support and attention.. Looking for steady rise
from here as near an official Launch Party next week...
Looking for news anytime now and surrounding the event starting 3-29. This will gain a lot of attention for PATRIOT.TV.
Also, the looking for news around the ROKU listing very soon...
🎉 It’s happening! The https://t.co/5RAXNKPHef Launch Party is here and you're invited! 🌟 Join us and an amazing lineup of speakers including Jason Lewis, Colonel John Mills, Roger Stone, and the esteemed Lt. Gen. Michael Flynn.
— PatriotTVNetwork (@patriottvnet) March 21, 2024
📆 Dates: March 29th and 30th
⏰ Times: Friday… pic.twitter.com/yf5s0awRnt
$RENB - Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace | NASDAQ https://www.nasdaq.com/press-release/cutting-edge-ai-company-gedicube-and-cyclomics-sign-binding-loi-to-join-forces-and-0
Technical Chart 100% BUY
https://www.barchart.com/stocks/quotes/ESM.TO/overview
💲$CBMJ~~CBMJ's Patriot.TV Welcomes Former US Congressman and Syndicated Broadcaster Jason Lewis as Host on Network Lineup; Brannon Howse Joins in Inaugural Show from Newly Built State of The Art Studio
https://www.accesswire.com/837349/cbmjs-patriottv-welcomes-former-us-congressman-and-syndicated-broadcaster-jason-lewis-as-host-on-network-lineup-brannon-howse-joins-in-inaugural-show-from-newly-built-state-of-the-art-studio
Press Release | 02/28/2024
VENICE, FL / ACCESSWIRE / February 28, 2024 / Conservative Broadcast Media & Journalism (OTC PINK:CBMJ) is pleased to announce that Patriot.TV proudly announces the addition of Jason Lewis, a distinguished drive time television host, to its roster. Jason Lewis is a seasoned broadcaster, former frequent guest host for Rush Limbaugh, and esteemed former member of the U.S. Congress.
JASON LEWIS LIVE
Jason Lewis garnered widespread recognition during his tenure at AM 1500 KSTP in the prominent Minneapolis/St. Paul market, commencing in 1994. Notably, in 2007, he stood out as one of the most frequently featured guest hosts for the renowned broadcaster, Rush Limbaugh. Subsequently, from 2009 until 2014, Jason hosted his own syndicated radio program. His illustrious career trajectory led to his election to the U.S. House of Representatives in 2016. In 2020, he emerged as the Minnesota Republican nominee for the U.S. Senate, narrowly missing victory in a historically challenging electoral landscape.
In a momentous occasion, President and Chief Operating Officer of Patriot.TV, Brannon Howse, joined Jason Lewis on his inaugural program on Monday night, February 26, 2024, extending a warm welcome to him on behalf of the network.
The inaugural show can be viewed at https://patriot.tv/programs/jason-lewis-live-02-26-2024-scotus-takes-on-big-tech-censorship-repeal-section-230?category_id=195658
Howse expressed his profound enthusiasm, stating, "Jason Lewis was the first individual I contacted upon assuming the role of President and Chief Operating Officer of Patriot.TV. Having known Jason personally for over two decades, I've engaged in numerous conversations with him regarding his potential return to the airwaves. This time everything lined up perfectly and I could not be more pleased."
Furthermore, Howse emphasized the network's commitment to excellence, remarking, "At Patriot.TV, we are setting the standard for conservative broadcast networks. From the unparalleled expertise of our talent to our cutting-edge broadcast production facilities, we are unmatched in today's conservative media landscape. The state-of-the-art studio in Florida that we built for Jason Lewis, complete with a sophisticated news desk and advanced camera technology, epitomizes our dedication to quality."
Illustrating the network's distinctive edge, Howse elaborated, "Our control room operators and production team operate on the latest equipment across two control rooms, supported by a graphics and production team that rivals any competitor. The recognition of our superior standards was underscored recently when a seasoned broadcaster expressed a desire to align with our team. In the coming weeks, we are excited to unveil the exceptional talent joining Patriot.TV."
During his inaugural program, Jason Lewis reflected on his transition from quasi-retirement, he underscored the critical juncture facing the nation in 2024, emphasizing the urgency to effect substantial change.
Jason Lewis elucidated, "Brannon Howse has been after me for a few years to do something like this. And when I saw the team, he put together his vision for Patriot.tv, I finally decided this was the right opportunity. So, Brannon Howse is the guy who convinced me to do this. And he's also the guy who is formulating this new network for people who want to save America. It's as simple as that. when I saw this team that Brannon Howse and General Michael Flynn were building, I said, 'all right, for 2024 and beyond, it's time to move the needle.'"
As part of the recently acquired assets from LTV Streaming, CBMJ recently acquired the platform Patriot.TV., a subscription-based streaming service.
About CBMJ: (CBMJ) Conservative Broadcast Media and Journalism is a media and web-based Patriot Company.
$AVRW: Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky
New TikTok Shop Ready for Launch to Help Grow Brand Awareness and Product Sales
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$CYIO -CYIOS leadership will continue working closely with digital marketing partner, INTENT SCIENCES with thorough GTM strategies in order to build brand awareness and to help grow the business online via SEO, social media, PR and media coverage over the next several months.
$CYIO the Final Beta testing nearly complete on Co’s much anticipated revamped carbon offset platform. Looking forward to enter phase 2 w/our leading digital mktg partners, to execute broad multi-month mktg plans including SEO, public relations & social media mktg.
$CYIO. Quick update: Final Beta testing nearly complete on Co’s much anticipated revamped carbon offset platform. Looking forward to enter phase 2 w/our leading digital mktg partners, to execute broad multi-month mktg plans including SEO, public relations & social media mktg.
— CYIOS Corporation (@cyioscorp) February 22, 2024
WATCH - Tucker Carlson in Congress
$NBIO (OTCQB:NBIO) ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral infections, announced today it has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company focused on precision biologics, to explore antibody-drug conjugates (ADCs) using Nascent's lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element.
Pritumumab (PTB) is a natural human antibody. This monoclonal antibody targets extracellular form of vimentin, a protein that has been linked to cancer growth and metastasis and is overexpressed in both brain and pancreatic cancers as well as other hard tumor cancers. PTB is a targeted immunotherapy that binds to vimentin in tumors and recruits the immune system to eliminate cancer cells. PTB has demonstrated a promising safety profile and preliminary efficacy in completed Phase I study in glioblastoma patients. Nascent has been recently cleared by the FDA to begin Phase II clinical trials for brain cancer.
In preclinical experiments, PTB antibody has shown the capacity to cross the blood-brain barrier with the additional potential to transport conjugated drugs into brain tissues, and Nascent holds a patent covering this specialized delivery mechanism. Under the terms of the agreement, Manhattan Bio will perform PTB conjugations to industry standard linker-payloads and will evaluate the resulting ADCs in the in vitro cell assays. The most promising candidates will be prioritized for further development for the treatment of vimentin-positive and potential secondary targets in advanced or metastatic tumors.
Nascent CEO, Sean Carrick, commented: "We are thrilled to unlock the full disruptive potential of pritumumab against cancer by collaborating with Manhattan Bio's world-leading scientists. This collaboration serves as an exciting first step in uncovering the possibilities of better targeted cancer therapies."
"Pritumumab offers unexplored potential as an ADC vector, and we are excited to test that promise leveraging our expertise in ADC discovery and development. This could pave the way for applying our newest linker-payload innovations to pritumumab in the future" said Dr. Borys Shor, CEO of Manhattan Bio.
$AVRW is set for a high growth sales and revenue year in 2024 based on all the positive groundwork that has been laid to date. The company's Seratopoical Revolution brand has clearly been demonstrated as top quality in terms of its formulations and performance, especially with the very high level endorsements that have been presented.
$AVRW Feature: Media Grabbing Seratopical Revolution Skin Care Line, Personal Choice of Nicole Kidman for Years, Now Directly Recommended by LeadingLA Plastic Surgeon for Superior Anti-Aging Results
https://news.columbusnewsonline.com/story/478529/media-grabbing-seratopical-revolution-skin-care-line-personal-choice-of-nicole-kidman-for-years-now-directly-recommended-by-leadingla-plastic-surgeon-for-superior-antiaging-results-avrw.html?utm_source=dlvr.it&utm_medium=twitter
From this article:
– Proprietary Nutraceutical & Topical Delivery Systems for Wellness and Anti-Aging Beauty Product Lines.
– Company Currently Holds 15 Patents.
– Seratopical Revolution Skin Care Products are Promoted by the Company’s Global Brand Ambassador and Strategic Partner Nicole Kidman.
– LA-Based Facial Plastic Surgeon Dr. Michael Persky Directly Supporting Latest Seratopical DNA Complex Product.
– Media Exposure in Top-Tier Publications Including CNN Underscored, Page Six, PEOPLE Magazine, and More.
– Q3 Net Revenue Increased Sequentially from Q2 2023.
– Sales Expected to Increase Significantly During Q4 and Into 2024.
– Gross Margin Increased 80 Basis Points Quarter-to-Quarter with Further Expansion Expected in Q4.
– Upcoming Launch of New Beauty Product Releases &New Marketing Initiatives.
– Latest Sales Results Show Accelerating Strength via New Marketing Campaigns
$SMME "The Federal Reserve's payment method report states that credit cards dominate while mobile payment apps hardly figure at all as a consumer payment method." -President and CEO, Chaya Hendrick. https://finance.yahoo.com/news/smartmetric-says-according-federal-credit-171300547.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance $LBPH $TSLA $SNGX $SGN $CING $HMLA
$MGRX MangoRx’s Brand and Products to be Featured by Dave Portnoy and Barstool Sports in the Weeks of Programming Around the Super Bowl
https://finance.yahoo.com/news/mangorx-brand-products-featured-barstool-130000834.html
~ From now through the Super Bowl $MGRX will be receiving massive exposure for their products
~ New Testosterone product "Prime" launch next Wen. Jan 31st and we can expect to see PR's and a big extended push of the product!
~ $MGRX is 56.1% Insider Owned
~ 59% Gross Margin
~ Offering closed from December
~ Innovative Treatments for Men. From Erectile Function to Hair Growth
$MGRX
$RWGI News: Rodedawg Intl. Ind, Inc. (OTC:RWGI) Acquires Parabola Mgmt., LLC
Acquisition Completes and Establishes Key Revenue Drivers
COSTA MESA, CA / ACCESSWIRE / December 27, 2023 / Rodedawg International Industries, Inc. (OTC PINK:RWGI) proudly announces the company has completed all terms and conditions of the Parabola Mgmt., LLC acquisition.
Chris Swartz, CEO, states: "We are proud to announce to our shareholders the completion of the acquisition of Parabola Mgmt. LLC. The acquisition included ownership of the California licensed cannabis company in Costa Mesa with options to purchase additional licenses. Most importantly, the Costa Mesa facility is now open, operational, and is geographically located in Southern California which is the #1 market in the world for cannabis. The completion of all terms for this acquisition of Parabola Mgmt. LLC is "the" major step for Rodedawg shareholders. Rodedawg now has a central sales hub for upcoming sales and distribution efforts. This has been a step-by-step process and we have strategically executed this key milestone. In addition to this acquisition, our shareholders can expect in the coming weeks that we will complete the acquisition of additional licensed cannabis distribution hubs and distribution contracts that will have 2024 revenues meet our stated goals of 7 million annually."
Chris Swartz, CEO, adds, "We want to remind our shareholders of the importance of these key milestones as we anticipate that these milestones completed during this 4th Quarter 2023 to be the catalyst of our company's revenue growth:
We are finalizing the agreements for distribution, management, and manufacturing of new cannabis products that increase revenues by an estimated 7 million dollars annually.
Our www.BrotherBuds.com team has finalized the product catalog and we will notify our shareholders of the launch of the cannabis delivery service.
We expect to announce acceptance of an offer for our new Healthcare Division Director. Primary responsibilities include the continued launch of and our flagship product of www.Elixicure.com, our topical pain relief brand.
We are currently in negotiation for an additional licensed cannabis distribution hub to be owned 100% by Rodedawg Intl. Ind. Inc.
Mr. Swartz concludes: "This is an exciting time for our company, and our team thanks our loyal shareholders for their ongoing support. We also want our shareholders to know that no reverse split is planned for the company."
About Rodedawg International Industries, Inc.
Rodedawg International Industries, Inc. (OTC PINK:RWGI) is focused on providing management services, acquisitions and restructuring resources throughout the regulated California cannabis market. We are a trusted partner and asset to licensed cultivation, distributors, manufacturers, and retail dispensaries.
Please note the company's Twitter address is https://twitter.com/RWGImerger for regular updates.
About Budding Horizon, LLC
Budding Horizon, LLC is California Limited Liability Company with offices in Orange County, California. The company is focused to providing management services for the licensed cannabis industry and seeks to leverage its expertise in the real estate acquisitions to acquire and develop a portfolio of assets.
The company website is https://buddinghorizon.com/
About Brother Buds
Brother Buds is a cannabis delivery service based in Costa Mesa, California. During the month of July 2023, the Rodedawg will operate Brother Buds under a non-storefront cannabis delivery license. The cannabis delivery service will focus on Los Angeles County, Orange County, and northern San Diego County in the demographic area of 23.86 million in 2019. The company is focused to providing management services for the licensed cannabis industry and seeks to leverage its expertise in the real estate acquisitions to acquire and develop a portfolio of assets.
The company website is https://BrotherBuds.com
Make sure to follow us at: https://twitter.com/BrotherBudsOC
Contact Information:
Rodedawg International Industries, Inc.
1-800-793-0355
ir@buddinghorizon.com
Safe Harbor Statement: In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Rodedawg International Industries, Inc.
via PRISM Mediawire, LLC
Profitable AI Company RTO's With OTC Co, 68K Shares At DTC!
Currently Only $150M Market Cap!
Name And Symbol Released Jan 1st
Happy New Year!!!!!
See Video => — Stock-Campaigns.ai (@GetInEarly) December 31, 2023
$MGRX news out today! MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT https://finance.yahoo.com/news/mangoceuticals-introduce-prime-powered-kyzatrex-123000672.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$MGRX Expands Reach: Launches New Hair Growth Product 'grow' And Strengthens Presence In Latin America With Mangorx Mexico $BLUE $GOTU $INVZ https://www.benzinga.com/pressreleases/23/12/36194628/mangoceuticals-mgrx-expands-reach-launches-new-hair-growth-product-grow-and-strengthens-presence-in via @Benzinga
$BRTX BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program https://ih.advfn.com/stock-market/NASDAQ/biorestorative-therapies-BRTX/stock-news/92787549/biorestorative-therapies-receives-a-notice-of-allo
$EVKRF: Soaring Lithium Demand Sets the Stage for Grid Metals Recent Acquisition in Lithium's "Silicon Valley"
Click here:
https://metalsmarketreaders.com/soaring-battery-metal-demand/?utm_source=corporateads&utm_medium=affiliate&utm_campaign=evkrf_us&utm_id=evkrf_us
$MGRX Our Unique Formula https://www.mangorx.com/hair-growth/
Followers
|
283
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
54890
|
Created
|
02/20/15
|
Type
|
Free
|
Moderator mick | |||
Assistants Nilbud ospreyeye jedijazz imgoingfishing1 PhotoChick $Pistol Pete$ |
WELCOME FRIENDS TO "MICK AND FRIENDS STOCK PICKS" BOARD !!!
PLEASE POST :
1. YOUR STOCK PICK
2. WHY YOU ARE RECOMMENDING THE STOCK
3. A BIT OF INFO ON STOCK WOULD BE HELPFUL
FORUM FOR ALL STOCKS:
- NYSE
- NASDAQ
- AMEX
- OTCBB
- PINK SHEETS
- GRAY SHEETS
- FOREIGN EXCHANGES
FORUM NOT FOR ANY SPECIFIC STOCK
PLEASE, YOUR POST MUST NOT CONTAIN ANYTHING ABOUT "BASHING" ON ANY I-HUB STOCK BOARD.
THANK YOU AND ENJOY "MICK AND FRIENDS STOCK PICKS" BOARD.
Mick
PhotoChick
http://investorshub.advfn.com/STOCKGOODIES-PLAYS-OF-THE-WEEK-18582/
Photo Chick
Ospreyeye
Pistol Pete
Nilbud
imgoingfishing1
RECOMMENDED LINKS:
- FEATURE HISTORIANS CREATURES HIGHLIGHTS: http://investorshub.advfn.com/Weekend-Warrior$-27071/
- BUD-X-EXCHANGE HUGE MARIJUANA CANNABIS HEMP FINDS
- STOCKGOODIES PLAYS OF THE WEEK
- http://Pennystocksinsiders.com
- Billionaire Boys Club Member Forum (BBCMF
- INTELLECTUAL STOCK INVESTOR { I S I
- $$$Ospreyeye: Charts, Technical Analysis & Japanese
-Best of iHub
Moderator: JAYLIN Assistants: OTCRIDDLER, OTC_Skywalker, Sonic Boom, norcalpsl, Penny Soldier
LINKS
http://www.thehotpennystocks.com/Stock-Quotes/?stock=VTPI
http://www.quotemedia.com/
http://www.quotemedia.com/finance/quote/?qm_page=73166&qm_symbol=EFFI
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Posts Today
|
0
|
Posts (Total)
|
54890
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |